BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cambridge Antibody Technology Group PLC  (CATG) And Debiopharm S.A. Enter Into An Exclusive Agreement To Develop And Market SC-1 For Gastric Carcinomas


10/16/2006 10:58:31 AM

LAUSANNE, Switzerland, and CAMBRIDGE, England, October 16 /PRNewswire/ -- The Debiopharm Group (Debiopharm), a global independent biopharmaceutical development company specialising in oncology and serious medical conditions and Cambridge Antibody Technology (CAT) have entered into an exclusive worldwide licensing agreement to develop and commercialise SC-1 and all derivative products generated by the use of the SC-1 Technology. SC-1, developed by Debiopharm, is a fully human monoclonal IgM antibody that targets CD55SC-1, a cell surface receptor specifically expressed on gastric carcinoma cells. Under the terms of the agreement, Debiopharm will receive upfront and milestone payments from CAT as well as royalties on potential future sales.

"CAT's expertise in the development of monoclonal antibodies gives us confidence for the future of SC-1 as a potential treatment for gastric cancer. As most patients diagnosed with stomach cancer fail to be cured by gastric resection, and most trials of pre- or post-surgery chemotherapy show no improvement in survival rates, there is a definite need for better treatment options," said Loic Maurel, CEO of The Debiopharm Group Canadian subsidiary.

"CAT is delighted with the agreement to develop and commercialise SC-1. This is a further step in enhancing our pipeline and builds on our recent product acquisitions in this area," commented Dr Richard Mason, Senior Vice President Business Development at CAT

SC-1 has completed a non-IND Phase I/II study in 51 resectable gastric cancer patients. SC-1 has been granted orphan drug designation by the US FDA for gastric cancer.

About The Debiopharm Group

The Debiopharm Group is a global biopharmaceutical development company that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.3 billion in 2005. For more information on the Debiopharm Group, please visit: www.debiopharm.com.

About CAT

CAT is a biopharmaceutical company using its capabilities and technologies in the discovery and development of new and innovative antibody medicines in selected therapeutic areas to bring improvements to seriously ill patients' lives. CAT is part of the AstraZeneca group of companies. CAT employs around 300 people and is based near Cambridge, UK and in Palo Alto, USA.

CAT is a leader in the discovery and development of human therapeutic antibodies and has an advanced proprietary platform technology for rapidly isolating human monoclonal antibodies using phage display and ribosome display systems. CAT has extensive phage antibody libraries, currently incorporating more than 100 billion distinct antibodies. These libraries form the basis for the Company's strategy to develop a portfolio of antibody-based drugs. For more information on CAT, please visit: www.cambridgeantibody.com.

The Debiopharm Group

CONTACT: Debiopharm Contacts Loic Maurel, President & CEO, DebiovisionInc., The Debiopharm Group, Tel.: +1-514-842-99-76, Fax: +1-514-842-54-30,lmaurel@debiovision.com; Jeff Skinner, Associate Director, BD&L,Debiovision Inc., The Debiopharm Group, Tel.: +1-514-842-99-76, Fax:+1-514-842-54-30, jskinner@debiovision.com; Additional Media Contacts InLondon: Maitland , Brian Hudspith, Tel: +44-(0)20-7379-5151,bhudspith@maitland.co.uk ; In New York: Noonan Russo, A division of EuroRSCG Life PR, Wendy Lau , Account Supervisor , Tel: +1-212-845-4272, Fax:+1-212-845-4260, wendy.lau1@eurorscg.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES